The addition of Gemtuzumab Ozogamicin to intensive chemotherapy in older patients with AML produces a significant improvement in overall survival: results of the UK NCRI AML16 randomized trial

Burnett, Alan Kenneth, Hills, Robert Kerrin ORCID: https://orcid.org/0000-0003-0166-0062, Hunter, Ann E., Milligan, Donald, Kell, William J., Wheatley, Keith, Yin, John L., Ali, Sahra, Kjeldsen, Lars, Bowen, David and Russell, Nigel H. 2011. The addition of Gemtuzumab Ozogamicin to intensive chemotherapy in older patients with AML produces a significant improvement in overall survival: results of the UK NCRI AML16 randomized trial. Blood -New York- 118 (21) , p. 268.

Full text not available from this repository.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Schools > Medicine
Subjects:	R Medicine > R Medicine (General) R Medicine > RC Internal medicine R Medicine > RC Internal medicine > RC0254 Neoplasms. Tumors. Oncology (including Cancer) R Medicine > RM Therapeutics. Pharmacology
Additional Information:	Conference: 53rd Annual Meeting and Exposition of the American-Society-of-Hematology (ASH)/Symposium on the Basic Science of Hemostasis and Thrombosis Location: San Diego, CA Date: DEC 10-13, 2011
Publisher:	American Society of Hematology
ISSN:	0006-4971
Last Modified:	24 Oct 2022 11:56
URI:	https://orca.cardiff.ac.uk/id/eprint/49786

Citation Data

Actions (repository staff only)

Edit Item